Market Cap : 67.21 B | Enterprise Value : 61.16 B | PE Ratio : 5.23 | PB Ratio : 3.75 |
---|
NAS:MRNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:MRNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Moderna's enterprise value is $61,164 Mil. Moderna's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $22,284 Mil. Therefore, Moderna's EV-to-Revenue for today is 2.74.
The historical rank and industry rank for Moderna's EV-to-Revenue or its related term are showing as below:
During the past 6 years, the highest EV-to-Revenue of Moderna was 848.62. The lowest was 2.08. And the median was 41.53.
MRNA's EV-to-Revenue is ranked better thanThe reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2022-08-12), Moderna's stock price is $171.81. Moderna's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $52.09. Therefore, Moderna's PS Ratio for today is 3.30.
The historical data trend for Moderna's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Moderna's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Moderna's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Moderna's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Moderna's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 61164.345 | / | 22284 | |
= | 2.74 |
Moderna's current Enterprise Value is $61,164 Mil.
Moderna's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $22,284 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Moderna's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 171.81 | / | 52.091 | |
= | 3.30 |
Moderna's share price for today is $171.81.
Moderna's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $52.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Moderna's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Gomez Jorge M | officer: See Remarks | C/O DENTSPLY SIRONA INC 13320 BALLANTYNE CORPORATE PLACE CHARLOTTE NC 28277 |
Burton Paul | officer: Chief Medical Officer | 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 |
Klinger Shannon Thyme | officer: Chief Legal Officer | 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139 |
Le Goff Corinne | officer: Chief Commercial Officer | 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139 |
Tallett Elizabeth E | director | 6705 ROCKLEDGE DR SUITE 900 BETHESDA MD 20817 |
Meline David W | officer: Chief Financial Officer | 3M COMPANY 3M OFFICE OF GENERAL COUNSEL ST PAUL MN 55144-1000 |
Horning Sandra | director | 333 LAKESIDE DRIVE FOSTER CITY CA 94404 |
Nader Francois | director | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Flagship Venturelabs Iv, Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143 |
Sagan Paul | director | AKAMAI TECHNOLOGIES INC 8 CAMBRIDGE CENTER CAMBRIDGE MA 02142 |
Ruiz Israel | director | C/O FORTIVE CORPORATION 6920 SEAWAY BOULEVARD EVERETT WA 98203 |
Zaks Tal Zvi | officer: Chief Medical Officer | C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX |
Nabel Elizabeth G | director | BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS ST BOSTON MA 02115 |
Hoge Stephen | officer: President | C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 |
Henderson Lori M. | officer: General Counsel and Secretary | MOLDFLOW CORP 430 BOSTON POST ROAD WAYLAND MA 01778 |
From GuruFocus
Other Sources
By Zacks 2022-04-01
By Zacks 2022-03-22
By Zacks 2022-03-17
By Zacks 2022-03-31
By Zacks 2022-03-18
By tipranks.com 2022-03-25
By Fool 2022-04-05
By Zacks 2022-03-30
By Zacks 2022-03-17
By Zacks 2022-03-23
By Zacks 2022-03-24
By Zacks 2022-03-23
By Zacks 2022-03-24
By Fool 2022-03-30